Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EBITDA Margin for 6 consecutive years, with 68.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 8527.0% year-over-year to 68.64%, compared with a TTM value of 31.92% through Dec 2025, down 2956.0%, and an annual FY2025 reading of 31.92%, down 2956.0% over the prior year.
  • EBITDA Margin was 68.64% for Q4 2025 at Cytek Biosciences, down from 8.83% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 16.63% in Q4 2024 and bottomed at 68.64% in Q4 2025.
  • Average EBITDA Margin over 5 years is 7.26%, with a median of 4.47% recorded in 2022.
  • The sharpest move saw EBITDA Margin skyrocketed 1619bps in 2021, then plummeted -8527bps in 2025.
  • Year by year, EBITDA Margin stood at 3.39% in 2021, then crashed by -95bps to 0.17% in 2022, then soared by 5638bps to 9.97% in 2023, then soared by 67bps to 16.63% in 2024, then crashed by -513bps to 68.64% in 2025.
  • Business Quant data shows EBITDA Margin for CTKB at 68.64% in Q4 2025, 8.83% in Q3 2025, and 10.99% in Q2 2025.